Elsevier

Biochemical Pharmacology

Volume 49, Issue 11, 26 May 1995, Pages 1545-1549
Biochemical Pharmacology

Commentary
Use of pure antioestrogens to elucidate the mode of action of oestrogens

https://doi.org/10.1016/0006-2952(94)00528-TGet rights and content

First page preview

First page preview
Click to open first page preview

References (54)

  • C.J. Newton et al.

    The unliganded estrogen receptor (ER) transduces growth factor signals

    J Steroid Biochem Mol Biol

    (1994)
  • G. Freiss et al.

    Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity

    Biochem Biophys Res Commun

    (1990)
  • L.R. Wiseman et al.

    Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells

    Eur J Cancer

    (1993)
  • B. Fisher et al.

    Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14

    J Natl Cancer Inst

    (1994)
  • A.E. Wakeling

    Pharmacology of antioestrogens

  • V.C. Jordan

    Biochemical pharmacology of antiestrogen action

    Pharmacol Rev

    (1984)
  • S.G. Nayfield et al.

    Potential role of tamoxifen in prevention of breast cancer

    J Natl Cancer Inst

    (1991)
  • V.C. Jordan

    A current view of tamoxifen for the treatment and prevention of breast cancer

    Br J Pharmacol

    (1993)
  • W.S. Branham et al.

    Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens

  • K.L. Kelner et al.

    Differential sensitivity of estrogen target tissues: The role of the receptor

    Endocrinology

    (1982)
  • A.E. Wakeling et al.

    A potent specific pure antiestrogen with clinical potential

    Cancer Res

    (1991)
  • M.J.K. Harper et al.

    A new derivative of triphenylethylene: Effect on implantation and mode of action in rats

    J Reprod Fertil

    (1967)
  • R.T. Turner et al.

    Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats

    J Bone Miner Res

    (1987)
  • S. Feldman et al.

    Antiestrogen and antiandrogen administration reduce bone mass in the rat

    Bone Miner

    (1989)
  • A.E. Wakeling

    The future of new pure antiestrogens in clinical breast cancer

    Breast Cancer Res Treat

    (1993)
  • A. Gallagher et al.

    The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

    Endocrinology

    (1993)
  • M. Dukes et al.

    Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones

    J Endocrinol

    (1994)
  • Cited by (0)

    View full text